Self-Emulsifying DIM Formulation to Prevent Aqueous Crystallization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Diindolylmethane (DIM) exhibits poor oral bioavailability due to its low solubility, rapid crystallization in aqueous environments, and susceptibility to presystemic metabolism, limiting its therapeutic and nutraceutical potential.
Innovation Solution
A self-emulsifying composition comprising diethylene glycol monoethyl ether, caprylocaproyl polyoxyl-8 glyceride, oleoyl polyoxyl-6 glyceride, a mixture of 12-hydroxystearic acid monoesters and diesters with macrogols, polyoxyethylene sorbitan monooleate, lauroyl polyoxyl-32 glyceride, and phosphatidyl choline, which upon dispersion in water, forms a stable oil-in-water emulsion with globules of 0.01 to 0.5 µm diameter, enhancing gastrointestinal absorption.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If DIM is formulated as crystalline solid or suspended in oil, then it can be administered orally, but it rapidly precipitates and re-crystalizes in aqueous environments resulting in poor bioavailability
Solution Approach 1:
The patent changes the physical state of DIM from crystalline solid to dissolved molecular form in a self-emulsifying carrier system. The carrier contains specific surfactants and co-surfactants that solubilize DIM, preventing crystallization upon contact with aqueous gastrointestinal fluids. This parameter change from solid to dissolved state resolves the contradiction by maintaining DIM in a bioavailable form throughout the digestive process.
Solution Approach 2:
The patent creates a composite self-emulsifying carrier system combining multiple components: surfactants (e.g., polysorbates, polyoxyl esters), co-surfactants (e.g., glycerol esters, medium-chain triglycerides), and DIM. This composite material works synergistically to prevent DIM crystallization in aqueous environments while maintaining oral administrability, thus resolving the bioavailability contradiction.
2Quantity of substance
If DIM is dissolved in organic solvents to improve solubility, then aqueous solubility increases, but DIM rapidly precipitates when exposed to aqueous media
Solution Approach 1:
The patent introduces surfactants and co-surfactants as intermediary substances that mediate between DIM and aqueous media. These intermediaries form micellar structures that solubilize DIM and prevent direct contact between DIM molecules and water, thereby preventing precipitation. The intermediaries maintain DIM in solution throughout the gastrointestinal tract.
Solution Approach 2:
The patent changes the solubility parameters of DIM by incorporating it into a self-emulsifying carrier with specific HLB-balanced surfactant and co-surfactant combinations. This parameter change enables DIM to remain solubilized in aqueous environments without rapid precipitation, resolving the contradiction between aqueous solubility and stability.
3Ease of operation
If conventional SEDDS or SMEDDS formulations are used, then spontaneous emulsification occurs, but unpredictable interactions between solvent oils, surfactants, and co-surfactants complicate formulation development
Solution Approach 1:
The patent optimizes the HLB parameters of the carrier system by selecting specific surfactant and co-surfactant combinations with complementary HLB values. This parameter optimization ensures predictable spontaneous emulsification behavior and minimizes formulation development complexity by establishing reliable formulation guidelines for DIM-containing self-emulsifying systems.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition significantly increases the oral bioavailability of DIM by preventing crystallization and improving systemic absorption, offering a well-tolerated, shelf-stable, and highly bioavailable formulation for pharmaceutical and nutraceutical use.
Implementation Method 1
self-emulsifying compositions of DIM showing improved bioavailability
Implementation Method 2
spontaneously emulsify on contact with aqueous media are referred to as self-emulsifying drug delivery systems (SEDDS)
Implementation Method 3
API solubilization behavior is assessed by in vitro digestion testing which allows measurement of solubilized drug concentrations released from the emulsion
Data Source
Figure 1
Figure 2
Figure 3
AI summary
Disclosed herein are self-emulsifying compositions and formulations of Dimdolylmethane ("DIM") and certain derivatives of DIM, their uses and methods of making. In particular, the disclosed compositions comprise a DIM-related indole as an active agent and a carrier, wherein the carrier comprises a solvent, one or more surfactants with an HLB of greater than 7, and one or more co-surfactants with an HLB equal to or less than 7. In certain aspects of the invention, the compositions disclosed herein show improved bioavailability.